Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2025
Spring on the Road
Spring Wellness 2025
Canada Votes 2025
2024 Readers' Choice Awards
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Class of 2025
Hammarskjold High School
Superior Collegiate and Vocational Institute
Westgate Collegiate & Vocational Institute
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Zai Lab Limited - American Depositary Shares
(NQ:
ZLAB
)
32.73
-1.35 (-3.96%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 11, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Zai Lab Limited - American Depositary Shares
< Previous
1
2
3
4
5
Next >
Zai Lab Announces Participation in March Investor Conference
March 06, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates
February 27, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab to Announce Full-Year 2023 Financial Results and Recent Corporate Updates on February 27, 2024
January 25, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC
January 10, 2024
From
Zai Lab Limited
Via
Business Wire
Zai Lab Limited (NASDAQ:ZLAB) Investor Alert: Investigation over Potential Wrongdoing
November 15, 2023
San Diego, CA -- (SBWIRE) -- 11/15/2023 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Zai Lab Limited.
Via
SBWire
Zai Lab Announces Participation in January Investor Conference
December 19, 2023
From
Zai Lab Limited
Via
Business Wire
Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA® in China’s National Reimbursement Drug List
December 13, 2023
From
Paratek Pharmaceuticals, Inc.
Via
GlobeNewswire
Zai Lab Announces the First Listing of VYVGART® (efgartigimod alfa injection) and Other Updates in China’s National Reimbursement Drug List
December 12, 2023
From
Zai Lab Limited
Via
Business Wire
Zai Lab Limited (NASDAQ:ZLAB) Investor Notice: Investigation over Possible Violations of Securities Laws
July 31, 2023
San Diego, CA -- (SBWIRE) -- 07/31/2023 -- Zai Lab Limited is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates
November 07, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab Announces Participation in November Investor Conferences
October 26, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab to Announce Third Quarter 2023 Financial Results and Recent Corporate Updates on November 7, 2023
October 18, 2023
- Company to Host Conference Call and Webcast on November 8, 2023, at 8:00 a.m. ET
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in China
September 18, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with NTRK-positive TKI-pretreated advanced solid tumors in China
August 30, 2023
Candidate precision medicine has shown encouraging clinical activity for both ROS1-positive NSCLC and NTRK fusion-positive advanced solid tumors
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab Announces Participation in September Investor Conferences
August 29, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab Announces Second Quarter 2023 Financial Results and Corporate Updates
August 07, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Zai Lab, Bowlero, and Chegg and Encourages Investors to Contact the Firm
August 06, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm
July 26, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm
July 21, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Zai Lab to Announce Second Quarter 2023 Financial Results and Corporate Updates on August 7, 2023
July 20, 2023
- Company to Host Conference Call and Webcast on August 8, 2023, at 8:00 a.m. ET
From
Zai Lab Limited
Via
GlobeNewswire
JAMA Oncology Publishes Data from Zai Lab Study Demonstrating Significant Reduction in Disease Progression or Death with ZEJULA (Niraparib) Maintenance Therapy in Broad Population of Advanced Ovarian Cancer Patients
July 19, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
July 17, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm
July 16, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Zai Lab Announces First Patient Treated in Mainland China for the Global Phase 3 FORTITUDE-101 Study of Bemarituzumab in First-Line Gastric Cancer
July 14, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm
July 10, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Zai Lab Announces Acceptance by China’s NMPA of the BLA for Efgartigimod Alfa Injection (Subcutaneous Injection) for Patients with Generalized Myasthenia Gravis
July 10, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab Announces Promotion of Yajing Chen to Chief Financial Officer
July 06, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm
July 05, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Zai Lab Limited Investors to Inquire About Securities Class Action Investigation - ZLAB
July 04, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Zai Lab Limited Investors to Inquire About Securities Class Action Investigation - ZLAB
July 03, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.